Gsa Capital Partners LLP Opti Nose, Inc. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

A detailed history of Gsa Capital Partners LLP transactions in Opti Nose, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 91,084 shares of OPTN stock, worth $34,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,084

Holding current value

$34,611

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$0.67 - $1.27 $61,026 - $115,676	91,084 New	91,084 $61,000
Q1 2024 May 03, 2024	BUY	$1.17 - $1.94 $60,458 - $100,247	51,674 Added 212.34%	76,010 $110,000
Q4 2023 Feb 16, 2024	BUY	$1.02 - $1.47 $24,822 - $35,773	24,336 New	24,336 $31,000
Q4 2021 Feb 14, 2022	SELL	$1.55 - $3.1 $817,541 - $1.64 Million	-527,446 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.16 $399,636 - $537,383	170,058 Added 47.58%	527,446 $1.58 Million
Q2 2021 Aug 05, 2021	BUY	$2.91 - $3.83 $708,704 - $932,762	243,541 Added 213.92%	357,388 $1.11 Million
Q1 2021 May 10, 2021	BUY	$3.47 - $4.75 $395,049 - $540,773	113,847 New	113,847 $420,000
Q2 2020 Aug 11, 2020	SELL	$3.58 - $7.44 $120,692 - $250,824	-33,713 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$3.49 - $9.2 $117,658 - $310,159	33,713 New	33,713 $151,000

Others Institutions Holding OPTN

# of Institutions

Shares Held

88.3M

Call Options Held

Put Options Held

Mvm Partners, LLC Boston, MA

14.6M
Shares

$5.55 Million
10.4% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

14.4M
Shares

$5.46 Million
0.57% of portfolio
Great Point Partners LLC Greenwich, CT

12.9M
Shares

$4.89 Million
3.98% of portfolio
Stonepine Capital Management, LLC Bend, OR

5.69M
Shares

$2.16 Million
2.41% of portfolio
Kingdon Capital Management, L.L.C. New York, NY

5.6M
Shares

$2.13 Million
0.45% of portfolio

View Full List

About OptiNose, Inc.

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $31.6M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

More about OPTN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account